期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 595, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ijpharm.2020.120181
关键词
In-situ solid lipid nanoparticles; Baicalein; Radioprotection; Radiosensitization; Pharmacodynamics; Thioredoxin reductase; ROS
资金
- Department of Atomic Energy, Government of India
- Board of Research in Nuclear Sciences (BRNS), DAE, Government of India [35/14/04/2015]
The use of in-situ solid lipid nanoparticles (SLNB) encapsulated baicalein (BCL) has been shown to provide significant radioprotection, enhance sensitivity of cancer cells to radiation, and potentially serve as an adjuvant therapy during cancer radiotherapy.
There is an unmet medical need for non-toxic and effective radiation countermeasures for prevention of radiation toxicity during planned exposures. We have earlier shown that intraperitoneal administration of baicalein (BCL) offers significant survival benefit in animal model. Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of baicalein has been reported in pre-clinical model systems and also in healthy human volunteers. However, clinical translation of baicalein is hindered owing to poor bioavailability due to lipophilicity. In view of this, we fabricated and characterized in-situ solid lipid nanoparticles of baicalein (SLNB) with effective drug entrapment and release kinetics. SLNB offered significant protection to murine splenic lymphocytes against 4 Gy ionizing radiation (IR) induced apoptosis. Oral administration of SLNB exhibited similar to 70% protection to mice against whole body irradiation (WBI 7.5 Gy) induced mortality. Oral relative bioavailability of BCL was enhanced by over similar to 300% after entrapment in the SLNB as compared to BCL. Oral dosing of SLNB resulted in transient increase in neutmphil abundance in peripheral blood. Interestingly, we observed that treatment of human lung cancer cells (A549) with radioprotective dose of SLNB exhibited radio-sensitization as evinced by decrease in survival and clonogenic potential. Contrary to antioxidant nature of baicalein in normal cells, SLNB treatment induced significant increase in cellular ROS levels in A549 cells probably due to higher uptake and inhibition of TrxR. Thus, a pharmaceutically acceptable SLNB exhibited improved bioavailability, better radioprotection to normal cells and sensitized cancer cells to radiation induced killing as compared to BCL suggesting its possible utility as an adjuvant during cancer radiotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据